{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:13:10Z","timestamp":1788581590808,"version":"build-2803163510"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072248"],"award-info":[{"award-number":["82072248"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"crossref","award":["139220012"],"award-info":[{"award-number":["139220012"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"crossref","award":["CGZH19005"],"award-info":[{"award-number":["CGZH19005"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Civil Aviation Flight University of China","award":["J2021-134"],"award-info":[{"award-number":["J2021-134"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the rifamycin cross-resistance in Helicobacter pylori, and whether the use of rifampicin E-test strips to screen H. pylori rifabutin resistance is appropriate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 89 H. pylori isolates were included. Rifampicin minimum inhibitory concentrations (MICs) were obtained by E-test, while the MICs for rifapentine, rifaximin, and rifabutin were determined by agar dilution method. The rifamycin resistance rates based on different breakpoints were compared. Isolates with high-level rifampicin resistance were subjected to whole-genome sequencing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A wide distribution of MICs (mostly in the range 0.125\u20138\u2005mg\/L) was observed for rifampicin, rifapentine, and rifaximin. Using MIC &amp;gt;1, \u2265 4, and &amp;gt; 4\u2005mg\/L as the breakpoints, resistance rates to rifampicin\/rifapentine\/rifaximin were 60.4%\/48.3%\/38.2%, 28.1%\/25.8%\/23.6%, and 15.7%\/16.9%\/7.9%, respectively. However, the rifabutin MICs of all the tested H. pylori isolates were extremely low (\u22640.016\u2005mg\/L). Applying MIC \u2265 0.125\u2005mg\/L as the breakpoint, rifabutin resistance was nil. No mutation was found in the rpoB gene sequences of the 2 isolates with high-level rifampicin resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is a lack of cross-resistance between rifabutin and other rifamycins in H. pylori. The use of rifampicin E-test to predict H. pylori rifabutin resistance is inappropriate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac417","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:03:52Z","timestamp":1670457832000},"page":"S479-S485","source":"Crossref","is-referenced-by-count":10,"title":["The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in <i>Helicobacter pylori<\/i>"],"prefix":"10.1093","volume":"226","author":[{"given":"Tiankuo","family":"Yang","sequence":"first","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Aviation Medical Appraisal Center, Civil Aviation Flight University of China , Guanghan , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Liu","sequence":"additional","affiliation":[{"name":"363 Hospital , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Shen","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Song","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Tang","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Benghezal","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry James","family":"Marshall","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Helicobacter pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Disease Research and Training, University of Western Australia , Nedlands , Australia"},{"name":"School of Biomedical Engineering, Marshall Laboratory of Biomedical Engineering, Shenzhen University Health Science Center , Shenzhen , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-5361","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"},{"name":"Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"2022120800034436000_jiac417-B1","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"2022120800034436000_jiac417-B2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"2022120800034436000_jiac417-B3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/pcmedi\/pbaa010","article-title":"Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections","volume":"3","author":"Yang","year":"2020","journal-title":"Precis Clin Med"},{"key":"2022120800034436000_jiac417-B4","doi-asserted-by":"crossref","first-page":"e12475","DOI":"10.1111\/hel.12475","article-title":"Fifth Chinese national consensus report on the management of Helicobacter pylori infection","volume":"23","author":"Liu","year":"2018","journal-title":"Helicobacter"},{"key":"2022120800034436000_jiac417-B5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/M19-3734","article-title":"Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial","volume":"172","author":"Graham","year":"2020","journal-title":"Ann Intern Med"},{"key":"2022120800034436000_jiac417-B6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/jcm8020199","article-title":"Rifabutin-based rescue therapy for Helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients","volume":"8","author":"Ribaldone","year":"2019","journal-title":"J Clin Med"},{"key":"2022120800034436000_jiac417-B7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejim.2020.06.029","article-title":"Rifabutin-based triple therapy or bismuth-based quadruple regimen as rescue therapies for Helicobacter pylori infection","volume":"81","author":"Saracino","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2022120800034436000_jiac417-B8","doi-asserted-by":"crossref","first-page":"e12719","DOI":"10.1111\/hel.12719","article-title":"Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: a prospective single-arm study","volume":"25","author":"Hirata","year":"2020","journal-title":"Helicobacter"},{"key":"2022120800034436000_jiac417-B9","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3390\/jcm11061658","article-title":"Experience with rifabutin-containing therapy in 500 patients from the European registry on Helicobacter pylori management (hp-EuReg)","volume":"11","author":"Nyssen","year":"2022","journal-title":"J Clin Med"},{"key":"2022120800034436000_jiac417-B10","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"2022120800034436000_jiac417-B11","doi-asserted-by":"crossref","first-page":"a027011","DOI":"10.1101\/cshperspect.a027011","article-title":"Rifamycins alone and in combination","volume":"6","author":"Rothstein","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2022120800034436000_jiac417-B12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ijantimicag.2009.12.017","article-title":"Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns","volume":"35","author":"Tupin","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2022120800034436000_jiac417-B13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2014.107","article-title":"Resistance to rifampicin: a review","volume":"67","author":"Goldstein","year":"2014","journal-title":"J Antibiot (Tokyo)"},{"key":"2022120800034436000_jiac417-B14","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.43.11.2813","article-title":"Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus","volume":"43","author":"Wichelhaus","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2022120800034436000_jiac417-B15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/AAC.11.5.773","article-title":"Permeability barrier to rifampin in mycobacteria","volume":"11","author":"Hui","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"2022120800034436000_jiac417-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1348-0421.1996.tb03303.x","article-title":"Different rifampicin inactivation mechanisms in Nocardia and related taxa","volume":"40","author":"Tanaka","year":"1996","journal-title":"Microbiol Immunol"},{"key":"2022120800034436000_jiac417-B17","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1073\/pnas.0711939105","article-title":"Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of arr","volume":"105","author":"Baysarowich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022120800034436000_jiac417-B18","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1128\/AAC.01166-12","article-title":"Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes","volume":"56","author":"Spanogiannopoulos","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022120800034436000_jiac417-B19","doi-asserted-by":"crossref","first-page":"e12451","DOI":"10.1111\/hel.12451","article-title":"Molecular characterization of Helicobacter pylori resistance to rifamycins","volume":"23","author":"Hays","year":"2018","journal-title":"Helicobacter"},{"key":"2022120800034436000_jiac417-B20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/jac\/dkm039","article-title":"Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany","volume":"59","author":"Glocker","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2022120800034436000_jiac417-B21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/IDR.S187063","article-title":"Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance","volume":"12","author":"Miftahussurur","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2022120800034436000_jiac417-B22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13756-019-0482-x","article-title":"Effective therapeutic regimens in two south Asian countries with high resistance to major Helicobacter pylori antibiotics","volume":"8","author":"Miftahussurur","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"2022120800034436000_jiac417-B23","doi-asserted-by":"crossref","first-page":"e0213868","DOI":"10.1371\/journal.pone.0213868","article-title":"Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican republic","volume":"14","author":"Miftahussurur","year":"2019","journal-title":"PLoS One"},{"key":"2022120800034436000_jiac417-B24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2217\/fmb-2020-0206","article-title":"Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population","volume":"15","author":"Tang","year":"2020","journal-title":"Future Microbiol"},{"key":"2022120800034436000_jiac417-B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000191204","article-title":"Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori","volume":"79","author":"Suzuki","year":"2009","journal-title":"Digestion"},{"key":"2022120800034436000_jiac417-B26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2022120800034436000_jiac417-B27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"2022120800034436000_jiac417-B28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2022120800034436000_jiac417-B29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/jcm8010053","article-title":"Genetic determinants and prediction of antibiotic resistance phenotypes in Helicobacter pylori","volume":"8","author":"Lauener","year":"2019","journal-title":"J Clin Med"},{"key":"2022120800034436000_jiac417-B30","doi-asserted-by":"crossref","first-page":"e12440","DOI":"10.1111\/hel.12440","article-title":"High primary antibiotic resistance of Helicobacter pylori strains isolated from dyspeptic patients: a prevalence cross-sectional study in Spain","volume":"22","author":"Mac\u00edas-Garc\u00eda","year":"2017","journal-title":"Helicobacter"},{"key":"2022120800034436000_jiac417-B31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jac\/49.3.541","article-title":"In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults","volume":"49","author":"Fujimura","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2022120800034436000_jiac417-B32","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jmii.2021.03.006","article-title":"Multidrug resistance: the clinical dilemma of refractory Helicobacter pylori infection","volume":"54","author":"Kuo","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"2022120800034436000_jiac417-B33","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3748\/wjg.v21.i9.2786","article-title":"Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study","volume":"21","author":"Zhang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2022120800034436000_jiac417-B34","doi-asserted-by":"crossref","first-page":"e12531","DOI":"10.1111\/hel.12531","article-title":"Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori","volume":"23","author":"Siavoshi","year":"2018","journal-title":"Helicobacter"},{"key":"2022120800034436000_jiac417-B35","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1128\/AAC.05437-11","article-title":"Helicobacter pylori resistance to rifabutin in the last 7 years","volume":"55","author":"Nishizawa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022120800034436000_jiac417-B36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/2050640615618043","article-title":"Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study","volume":"4","author":"Mori","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"2022120800034436000_jiac417-B37","doi-asserted-by":"crossref","first-page":"e12660","DOI":"10.1111\/hel.12660","article-title":"Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018","volume":"24","author":"Lee","year":"2019","journal-title":"Helicobacter"},{"key":"2022120800034436000_jiac417-B38","doi-asserted-by":"crossref","first-page":"9351801","DOI":"10.1155\/2019\/9351801","article-title":"Rifabutin and furazolidone could be the candidates of the rescue regimen for antibiotic-resistant H. pylori in Korea","volume":"2019","author":"Choi","year":"2019","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2022120800034436000_jiac417-B39","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"Kunin","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2022120800034436000_jiac417-B40","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/AAC.43.5.1072","article-title":"In vitro anti\u2013Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657","volume":"43","author":"Akada","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2022120800034436000_jiac417-B41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the treatment of Helicobacter pylori infection: a review","volume":"10","author":"Gisbert","year":"2020","journal-title":"Pathogens"},{"key":"2022120800034436000_jiac417-B42","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211044064","article-title":"Comments regarding use of rifabutin for Helicobacter pylori eradication","volume":"14","author":"Graham","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2022120800034436000_jiac417-B43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/hel.12147","article-title":"Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori","volume":"19","author":"Lim","year":"2014","journal-title":"Helicobacter"},{"key":"2022120800034436000_jiac417-B44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/hel.12296","article-title":"Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies","volume":"21","author":"Ciccaglione","year":"2016","journal-title":"Helicobacter"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_5\/S479\/47255484\/jiac417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/Supplement_5\/S479\/47255484\/jiac417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:04:08Z","timestamp":1670457848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/Supplement_5\/S479\/6845444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":44,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2022,12,8]]},"published-print":{"date-parts":[[2022,12,8]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac417","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,15]]},"published":{"date-parts":[[2022,12,8]]}}}